Nurix Therapeutics (NASDAQ: NRIX) shares NX-5948 Phase 1 update deck

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. is planning meetings with securities analysts, investors and others beginning on September 3, 2025 and will use an updated investor presentation in those discussions. The presentation focuses on clinical development plans for bexobrutideg (NX-5948), an investigational oral, brain-penetrant degrader of Bruton's tyrosine kinase that is in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies. The investor presentation is provided as Exhibit 99.1 and is furnished under a Regulation FD disclosure, rather than being treated as filed under the securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001549595false00015495952025-09-032025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 3, 2025

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1700 Owens Street, Suite 205 San Francisco, California						94158
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01    Regulation FD Disclosure.

Nurix Therapeutics, Inc. (the “Company”) intends to conduct meetings with securities analysts, investors and others beginning on September 3, 2025. As part of these meetings, the Company intends to utilize an investor presentation (the “Investor Presentation”) which includes updates about the Company’s clinical development plans for bexobrutideg (NX-5948), its investigational oral, brain-penetrant degrader of Bruton's tyrosine kinase, which is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:

Exhibit No.						Exhibit Title or Description
99.1						Nurix Therapeutics, Inc. Investor Presentation dated September 3, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: September 3, 2025			By:			/s/ Christine Ring
						Christine Ring, Ph.D., J.D.
						Chief Legal Officer

3

FAQ

What does Nurix Therapeutics (NRIX) disclose in this 8-K?

The company describes plans to meet with securities analysts, investors and others beginning on September 3, 2025, and notes it will use an updated investor presentation during these meetings.

What is the focus of Nurix Therapeutics' new investor presentation?

The presentation highlights updated clinical development plans for bexobrutideg (NX-5948), Nurix's investigational oral, brain-penetrant degrader of Bruton's tyrosine kinase.

What stage of development is bexobrutideg (NX-5948) in for NRIX?

Bexobrutideg (NX-5948) is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.

How is the NRIX investor presentation made available in this 8-K?

The investor presentation is included as Exhibit 99.1 and is incorporated by reference, providing access to the updated clinical and corporate information shared with investors.

Is the Nurix Therapeutics investor information considered filed with the SEC?

The information under Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is specified as not being deemed “filed” for purposes of Section 18 of the Exchange Act.

Does this NRIX 8-K include any other exhibits?

Yes. In addition to the investor presentation in Exhibit 99.1, the filing includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.